Butyltolylquinuclidine

2-Butyl-3-(p-tolyl)quinuclidine (BTQ) is a stimulant DRI.[1] It is one of a number of substituted quinuclidine derivatives developed as potential medications for the treatment of cocaine abuse,[2] and produces similar effects to cocaine in animal studies, although milder and longer-lasting.

Butyltolylquinuclidine
Clinical data
ATC code
  • none
Legal status
Legal status
  • In general: legal
Identifiers
PubChem CID
ChemSpider
Chemical and physical data
FormulaC18H27N
Molar mass257.414 g/mol g·mol−1
3D model (JSmol)
  (verify)

See also

References
  1. Sakamuri, S.; Enyedy, I. J.; Zaman, W. A.; Tella, S. R.; Kozikowski, A. P.; Flippen-Anderson, J. L.; Farkas, T.; Johnson, K. M.; Wang, S. (2003). "2,3-Disubstituted quinuclidines as a novel class of dopamine transporter inhibitors". Bioorganic & Medicinal Chemistry. 11 (6): 1123–1136. doi:10.1016/S0968-0896(02)00450-9. PMID 12614900.
  2. Enyedy, I. J.; Sakamuri, S.; Zaman, W. A.; Johnson, K. M.; Wang, S. (2003). "Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors". Bioorganic & Medicinal Chemistry Letters. 13 (3): 513–517. doi:10.1016/S0960-894X(02)00943-5. PMID 12565962.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.